Feline Upper Respiratory Infection (URI): Etiology, Diagnosis, and Management

Introduction

Feline upper respiratory infection (URI) represents a complex, multifactorial disease syndrome that is among the most common infectious conditions encountered in domestic cats. The term "what is a respiratory infection in cats" encompasses a clinical presentation characterized by inflammation of the nasal passages, pharynx, larynx, and conjunctival mucosa. The disease is caused by a diverse array of primary viral and bacterial pathogens, often acting in concert with opportunistic secondary invaders. Understanding the etiological agents, their pathophysiological mechanisms, and the diagnostic and therapeutic approaches is essential for effective clinical management and population-level control.

Etiology

The etiology of feline URI is dominated by two viral agents: feline herpesvirus type 1 (FHV-1) and feline calicivirus (FCV). These viruses account for approximately 80 to 90 percent of all clinical cases. Bacterial pathogens, including Bordetella bronchiseptica and Chlamydia felis, are recognized as primary or contributory agents in a significant subset of cases. Mixed infections involving multiple pathogens are common.

Viral Pathogens

Feline herpesvirus type 1 is an enveloped, double-stranded DNA virus belonging to the family Herpesviridae, subfamily Alphaherpesvirinae. The virus exhibits a predilection for epithelial cells of the upper respiratory tract and conjunctiva. Following acute infection, FHV-1 establishes lifelong latency in the trigeminal ganglia, with reactivation occurring during periods of stress or immunosuppression. Feline calicivirus is a non-enveloped, single-stranded positive-sense RNA virus in the family Caliciviridae. FCV demonstrates significant antigenic diversity and mutates rapidly, leading to the emergence of variant strains with variable virulence. Both viruses are shed in ocular, nasal, and oral secretions.

Bacterial Pathogens

Bordetella bronchiseptica is a Gram-negative, aerobic coccobacillus that colonizes the ciliated respiratory epithelium. The bacterium produces several virulence factors, including adhesins and a dermonecrotic toxin, which impair mucociliary clearance and facilitate secondary infection. Chlamydia felis is an obligate intracellular Gram-negative bacterium that primarily targets conjunctival epithelial cells, causing intense conjunctivitis. Mycoplasma species, particularly Mycoplasma felis, are also implicated as opportunistic pathogens in feline URI. Secondary bacterial infections with commensal flora such as Pasteurella multocida, Streptococcus species, and Escherichia coli frequently complicate viral URI.

Epidemiology and Transmission

Feline URI is highly contagious and is transmitted primarily through direct contact with infected secretions, fomites, and aerosolized droplets. The incubation period ranges from 2 to 10 days depending on the pathogen and host immune status. Shelters, multi-cat households, and catteries represent high-risk environments where transmission is amplified by crowding, stress, and suboptimal ventilation. Young kittens, geriatric cats, and immunocompromised individuals are disproportionately affected. Carrier states are common for FHV-1 and FCV, with latent FHV-1 reactivation serving as a source of intermittent shedding.

Clinical Signs

The clinical presentation of feline URI is variable and depends on the causative agent, host factors, and the presence of coinfections. Common clinical signs include serous to mucopurulent ocular and nasal discharge, sneezing, conjunctival hyperemia, chemosis, and blepharospasm. FHV-1 infection is classically associated with severe conjunctivitis, corneal ulceration (dendritic ulcers), and stromal keratitis. FCV infection more frequently presents with oral ulceration (particularly on the tongue and hard palate), hypersalivation, and gingivitis. Systemic signs such as pyrexia, lethargy, and anorexia are common. Bordetella bronchiseptica infection may produce a prominent cough and tracheobronchitis, whereas Chlamydia felis predominantly causes conjunctivitis with minimal upper respiratory signs.

Pathology

The pathological changes in feline URI reflect the tropism of the infecting agents for mucosal epithelium. FHV-1 induces lytic infection of epithelial cells, resulting in multifocal necrosis, neutrophilic infiltration, and syncytial cell formation. Corneal involvement leads to epithelial ulceration and stromal edema. FCV causes vesicle formation and ulceration of oral and respiratory epithelium, with intracytoplasmic inclusion bodies occasionally observed. Bordetella bronchiseptica infection results in ciliary stasis, epithelial necrosis, and purulent exudate within the airways. Chlamydia felis infection elicits a marked lymphoplasmacytic and neutrophilic conjunctival inflammatory response with characteristic intracytoplasmic elementary bodies.

Diagnosis

Accurate diagnosis of feline URI requires a combination of clinical assessment, cytology, and molecular or serological testing. The diagnostic approach is guided by the severity and chronicity of signs, the number of animals affected, and the need to identify specific pathogens for treatment or control purposes.

Clinical Examination and Cytology

A thorough physical examination should include assessment of the eyes, nose, oral cavity, and pharynx. Conjunctival and corneal staining with fluorescein is essential to detect ulcerative keratitis. Cytological examination of conjunctival scrapings or nasal exudate can reveal intracytoplasmic inclusion bodies suggestive of Chlamydia felis or neutrophilic inflammation with intracellular bacteria indicative of Bordetella bronchiseptica.

Molecular Diagnostics

Polymerase chain reaction (PCR) assays are the gold standard for detecting FHV-1, FCV, Bordetella bronchiseptica, and Chlamydia felis from conjunctival, nasal, or oropharyngeal swabs. Real-time PCR offers high sensitivity and specificity, allowing for quantification of pathogen load. Multiplex PCR panels enable simultaneous detection of multiple agents in a single reaction. Sample quality is critical; swabs should be collected from actively inflamed mucosa and placed in appropriate transport media.

Serology

Serological testing for antibodies against FHV-1 and FCV is of limited diagnostic utility in individual cases due to widespread vaccination and prior exposure. Paired serology (acute and convalescent) may support a diagnosis of recent infection in unvaccinated populations. Detection of Chlamydia felis antibodies via immunofluorescence or ELISA can be useful in outbreak investigations.

Virus Isolation and Bacterial Culture

Virus isolation in cell culture is available but is slower and less sensitive than PCR. Bacterial culture with antimicrobial susceptibility testing is indicated when Bordetella bronchiseptica or secondary bacterial pathogens are suspected, particularly in cases of chronic or refractory disease.

Diagnostic Algorithm

The following Mermaid diagram outlines a diagnostic decision tree for feline URI.

flowchart TD
    A[Clinical signs of URI], > B{Severity and duration}
    B, >|Mild, acute| C[Supportive care, monitor]
    B, >|Moderate to severe| D[Ophthalmic exam, fluorescein stain]
    D, > E{Corneal ulcer present?}
    E, >|Yes| F[PCR for FHV-1, FCV]
    E, >|No| G[Conjunctival/nasal swab for PCR]
    G, > H[Multiplex PCR: FHV-1, FCV, Bordetella, Chlamydia]
    H, > I[Positive result]
    H, > J[Negative result]
    I, > K[Targeted therapy]
    J, > L[Cytology, bacterial culture]
    L, > M[Identify secondary bacteria or Mycoplasma]
    M, > N[Antimicrobial therapy based on sensitivity]

Treatment

The management of feline URI is primarily supportive, with antimicrobial therapy reserved for confirmed or suspected bacterial involvement. Antiviral agents may be used in specific cases of FHV-1 infection.

Supportive Care

Supportive care is the cornerstone of treatment. This includes ensuring adequate hydration and nutritional intake, providing environmental humidity (nebulization), and gently cleaning ocular and nasal discharge. Appetite stimulants and assisted feeding may be necessary in anorexic cats. Severe cases may require hospitalization for intravenous fluid therapy and nutritional support.

Antimicrobial Therapy

Doxycycline is the first-line antimicrobial for Bordetella bronchiseptica and Chlamydia felis infections. The recommended dosage is 5 to 10 mg/kg orally every 12 to 24 hours. Tetracyclines are contraindicated in young kittens due to the risk of dental staining. Azithromycin (5 to 10 mg/kg orally every 24 to 48 hours) is an alternative. For secondary bacterial infections, antimicrobial selection should be guided by culture and susceptibility testing. Empirical therapy with amoxicillin-clavulanate or a fluoroquinolone may be considered pending results.

Antiviral Therapy

Systemic antiviral therapy for FHV-1 is limited by efficacy and toxicity. Famciclovir, a prodrug of penciclovir, has demonstrated efficacy in reducing clinical signs and viral shedding in experimentally infected cats. The recommended dosage is 40 to 90 mg/kg orally every 8 to 12 hours. Topical antiviral agents such as cidofovir or trifluridine ophthalmic solutions may be used for herpetic keratitis. Interferon-omega has been investigated as an adjunctive therapy but evidence for its efficacy is limited.

Adjunctive Therapies

Lysine supplementation has been historically recommended for FHV-1 management based on in vitro antagonism of arginine. However, clinical trials have failed to demonstrate consistent benefit, and its routine use is no longer recommended. Nebulization with saline or antimicrobials may provide symptomatic relief. Nonsteroidal anti-inflammatory drugs may be used cautiously to reduce fever and inflammation.

Control and Prevention

Control of feline URI relies on vaccination, biosecurity, and environmental management.

Vaccination

Modified-live and inactivated vaccines are available for FHV-1 and FCV. Vaccination reduces the severity of clinical disease but does not prevent infection or shedding. Vaccines for Bordetella bronchiseptica (intranasal or parenteral) and Chlamydia felis are available and may be indicated in high-risk populations. Core vaccination protocols recommend FHV-1 and FCV vaccination for all cats.

Biosecurity

In shelter and multi-cat environments, isolation of affected individuals, strict hand hygiene, and disinfection of surfaces are critical. FHV-1 is inactivated by most disinfectants, but FCV is resistant to many common agents. Sodium hypochlorite (bleach) at a 1:32 dilution is effective against FCV. Adequate ventilation and reduction of stocking density reduce transmission risk.

Stress Reduction

Minimizing stress through environmental enrichment, consistent routines, and reducing overcrowding decreases the likelihood of FHV-1 reactivation and clinical disease.

Prognosis

The prognosis for uncomplicated feline URI is generally good, with most cats recovering within 7 to 14 days with supportive care. Chronic or recurrent disease is common in FHV-1 infected cats due to viral latency. Severe cases, particularly in kittens or immunocompromised animals, may result in chronic rhinitis, sinusitis, or corneal scarring. Fatal outcomes are rare but can occur in neonates or in outbreaks of virulent FCV strains.

Conclusion

Feline upper respiratory infection is a common, multifactorial syndrome with significant implications for individual animal welfare and population health. A thorough understanding of the etiological agents, their transmission dynamics, and the diagnostic tools available is essential for effective management. Treatment is largely supportive, with targeted antimicrobial and antiviral therapy reserved for specific indications. Vaccination and biosecurity remain the most effective strategies for prevention and control.

References

1. Gaskell R, Dawson S, Radford A. Feline respiratory disease. In: Greene CE, editor. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier Saunders; 2012. p. 151-162.
2. Sykes JE. Feline upper respiratory tract infections. In: Sykes JE, editor. Canine and Feline Infectious Diseases. St. Louis: Elsevier Saunders; 2014. p. 191-204.
3. Lappin MR, Blondeau J, Boothe D, et al. Antimicrobial use guidelines for treatment of respiratory tract disease in dogs and cats: antimicrobial guidelines working group of the International Society for Companion Animal Infectious Diseases. J Vet Intern Med. 2017;31(2):279-294.
4. Maggs DJ. Ocular manifestations of feline upper respiratory tract infections. Vet Clin North Am Small Anim Pract. 2005;35(1):101-121.
5. Helps CR, Lait P, Damhuis A, et al. Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, Chlamydia felis and Bordetella bronchiseptica in cats: experience from 218 European catteries. Vet Rec. 2005;156(21):669-673.
6. Binns SH, Dawson S, Speakman AJ, et al. A study of feline upper respiratory tract disease with reference to prevalence and risk factors for infection with feline calicivirus and feline herpesvirus. J Feline Med Surg. 2000;2(3):123-133.
7. Veir JK, Lappin MR. Feline herpesvirus-1 infection. In: Bonagura JD, Twedt DC, editors. Kirk's Current Veterinary Therapy XV. St. Louis: Elsevier Saunders; 2014. p. 1273-1277.
8. Radford AD, Coyne KP, Dawson S, et al. Feline calicivirus. Vet Res. 2007;38(2):319-335.
9. Foley JE, Rand C, Bannasch MJ, et al. Molecular epidemiology of feline bordetellosis in two animal shelters in California, USA. Prev Vet Med. 2002;54(2):141-156.
10. Sykes JE, Anderson GA, Studdert VP, et al. Prevalence of feline Chlamydia psittaci and feline herpesvirus 1 in cats with upper respiratory tract disease. J Vet Intern Med. 1999;13(3):153-162.
11. Hartmann AD, Hawley J, Werckenthin C, et al. Detection of bacterial and viral pathogens from cats with upper respiratory tract disease using a real-time PCR panel. J Vet Diagn Invest. 2010;22(6):891-896.
12. Malik R, Lessels NS, Webb S, et al. Treatment of feline herpesvirus-1 associated disease in cats with famciclovir. Vet Rec. 2009;164(12):359-362.
13. Thomasy SM, Lim CC, Reilly CM, et al. Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1. Am J Vet Res. 2011;72(1):85-95.
14. Stiles J. Treatment of cats with ocular disease attributable to feline herpesvirus type 1. J Am Vet Med Assoc. 2003;222(11):1544-1547.
15. Sparkes AH, Caney SM, Sturgess CP, et al. The clinical efficacy of dietary L-lysine in the prevention of feline herpesvirus infection. J Feline Med Surg. 2007;9(1):1-6.
16. Thiry E, Addie D, Belák S, et al. Feline herpesvirus infection. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):547-555.
17. Radford AD, Addie D, Belák S, et al. Feline calicivirus infection. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):556-564.
18. Egberink H, Addie D, Belák S, et al. Bordetella bronchiseptica infection in cats. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):610-614.
19. Gruffydd-Jones T, Addie D, Belák S, et al. Chlamydophila felis infection. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):605-609.
20. Dinnage JD, Scarlett JM, Richards JR. Descriptive epidemiology of feline upper respiratory tract disease in an animal shelter. J Feline Med Surg. 2009;11(10):816-825.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.